Change search
ReferencesLink to record
Permanent link

Direct link
High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
KTH, School of Biotechnology (BIO), Proteomics (closed 20130101). KTH, Centres, Science for Life Laboratory, SciLifeLab.ORCID iD: 0000-0001-8993-048X
Show others and affiliations
2011 (English)In: Diagnostic Pathology, ISSN 1746-1596, Vol. 6, 91- p.Article in journal (Refereed) Published
Abstract [en]

Background: High expression of the RNA-binding protein RBM3 has previously been found to be associated with good prognosis in breast cancer, ovarian cancer, malignant melanoma and colorectal cancer. The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer. Findings: Immunohistochemical RBM3 expression was examined in a tissue microarray with malignant and benign prostatic specimens from 88 patients treated with radical prostatectomy for localized disease. While rarely expressed in benign prostate gland epithelium, RBM3 was found to be up-regulated in prostate intraepithelial neoplasia and present in various fractions and intensities in invasive prostate cancer. High nuclear RBM3 expression was significantly associated with a prolonged time to biochemical recurrence (BCR) (HR 0.56, 95% CI: 0.34-0.93, p = 0.024) and clinical progression (HR 0.09, 95% CI: 0.01-0.71, p = 0.021). These associations remained significant in multivariate analysis, adjusted for preoperative PSA level in blood, pathological Gleason score and presence or absence of extracapsular extension, seminal vesicle invasion and positive surgical margin (HR 0.41, 95% CI: 0.19-0.89, p = 0.024 for BCR and HR 0.06, 95% CI: 0.01-0.50, p = 0.009 for clinical progression). Conclusion: Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3 for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in larger studies.

Place, publisher, year, edition, pages
2011. Vol. 6, 91- p.
Keyword [en]
RBM3, immunohistochemistry, prognosis, prostate cancer
National Category
Medical Biotechnology
URN: urn:nbn:se:kth:diva-45598DOI: 10.1186/1746-1596-6-91ISI: 000295922500001ScopusID: 2-s2.0-80053380290OAI: diva2:453939
Knut and Alice Wallenberg FoundationSwedish Research CouncilScience for Life Laboratory - a national resource center for high-throughput molecular bioscience
QC 20111104Available from: 2011-11-04 Created: 2011-10-31 Last updated: 2011-12-07Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Uhlén, Mathias
By organisation
Proteomics (closed 20130101)Science for Life Laboratory, SciLifeLab
In the same journal
Diagnostic Pathology
Medical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 34 hits
ReferencesLink to record
Permanent link

Direct link